The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal.
J
J
Harenberg
D001675:Bioethics; D001835:Body Weight; D017985:Dalteparin / Q000008:administration & dosage* / Q000009:adverse effects; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007258:Informed Consent; D009765:Obesity / Q000150:complications; D010314:Partial Thromboplastin Time; D012189:Retrospective Studies; D012449:Safety; D013997:Time Factors; D020246:Venous Thrombosis / Q000188:drug therapy
D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D015951:Factor Xa; D017985:Dalteparin